Risk Factors and Material Contracts
The following summary of risk factors and material contracts is provided for current shareholders, prospective partners, and other parties with a professional interest in Jurassic Meat. It is derived from disclosures prepared in connection with the company's private financings. It is not complete, it is not an offer to sell or a solicitation of an offer to buy any security, and it should be read together with the forward-looking statements notice on the Investor Relations page.
Risk factors
An investment in, or commercial relationship with, Jurassic Meat involves a high degree of risk. The risks described below are not the only ones we face. Additional risks not presently known to us, or that we currently deem immaterial, may also adversely affect our business, financial condition, and results of operations.
Risks related to our business and industry
1. We have a limited operating history at commercial scale, and we may not achieve consistent production yields. We completed our first production campaigns at our Pingshan production facility in 2025 and launched our first commercial products in December 2026. Our production process depends on continuous bioreactor campaigns of 18 to 24 days, the outcomes of which are subject to biological variability. Campaigns that fall outside our expected window, or lots that meet food-safety standards but fail sensory evaluation and are therefore not released, reduce the volume available for sale. We have limited historical data from which to forecast yields, and there can be no assurance that our production will reach the levels required to support our commercial plans.
2. Consumer acceptance of meat derived from extinct species is unproven and may develop more slowly than anticipated, or not at all. We have limited ability to predict consumer acceptance of meat from species that have been extinct for more than 66 million years. Our products contain protein from species with no history of human consumption, and there is no established market, consumer research base, or culinary precedent for them. Consumers, chefs, retailers, and regulators may be unwilling to accept our products for reasons including unfamiliarity, perceived safety concerns, ethical or religious objections, or associations with works of fiction. If our products do not achieve sufficient acceptance, our business would be materially and adversely affected.
3. Our initial distribution is concentrated among a small number of partner restaurants and food-service partners. We currently supply our products by allocation to a limited number of partners. The loss of, or a significant reduction in demand from, any of these partners, or reputational harm suffered by any of them, could adversely affect our revenue and brand. Our allocation model may also limit our ability to respond to changes in demand.
4. We depend on a limited number of suppliers for critical inputs, including porcine bone scaffolds, serum-free media components, and farmed alligator. Our Bone-In Ribs require a food-grade porcine bone scaffold that we obtain from a single qualified supplier under a master services agreement. Certain serum-free media components are available from a limited number of qualified sources. The farmed American alligator used in our Blended Sausage is supplied exclusively by Myakka River Alligator Co. Any interruption in supply, change in specification, failure to meet our quality or provenance standards, or termination of these relationships could delay or halt production of affected products, and qualifying an alternative source could take considerable time.
5. Our production operations depend on a third-party contract operator. Our Pingshan production facility is operated under a contract-operations agreement with Linjiang Bioprocess Operations Co., Ltd., which employs the approximately 150 operators and technicians who staff the facility under the direction of our manufacturing personnel. We do not directly employ these individuals. Any failure by Linjiang to perform under the agreement, any labor dispute, turnover, or change in control affecting Linjiang, or any termination or non-renewal of the agreement, could disrupt our production. Transitioning to another operator, or to direct employment, would require significant time, cost, and management attention, and could expose us to the loss of process knowledge.
Risks related to regulation
6. Regulatory frameworks for cultivated meat and novel foods are evolving, and changes could delay, restrict, or prevent market access. Our products are subject to pre-market review or authorization in many jurisdictions, including as novel foods and, where applicable, as foods derived from genetically modified cell lines. Because our products are derived from extinct species, regulators may apply frameworks not designed for them, may require data we do not possess or cannot readily generate, or may decline to act. Jurisdictional questions arising from the porcine scaffold in our bone-in products and the farmed alligator in our Blended Sausage may further complicate review.
7. Certain jurisdictions prohibit the manufacture or sale of cultivated meat, and additional jurisdictions may do so. Legislation enacted in Florida in 2024 prohibits the manufacture, sale, holding, and distribution of cultivated meat in that state, and other U.S. states, including Alabama, have adopted similar restrictions. Our Blended Sausage is not sold in Florida, notwithstanding that its alligator component is sourced from a Florida supplier. Further state, national, or supranational prohibitions, or labeling restrictions on the use of terms such as "meat," could limit our addressable markets, complicate our supply chain, and increase our compliance costs.
8. We are subject to food-safety, allergen, and labeling requirements that may be interpreted differently across jurisdictions, and we may be subject to recalls. We are subject to extensive food-safety and labeling laws in each market in which our products are sold. Our disclosures, including our scaffold material disclosure and our statements regarding species with no history of human consumption, may be interpreted differently by different authorities. Unidentified allergenicity or other adverse reactions to novel proteins could emerge only after broader consumption. Any recall, whether voluntary or mandated, and whether or not related to an actual safety issue, could result in significant costs and reputational harm.
Risks related to our international operations
9. Our research and production operations are located in Shenzhen, China, and are exposed to geopolitical, trade, and cross-border risks. Substantially all of our research and production takes place in Shenzhen under local research authorization and the Biosafety Law of the People's Republic of China. Changes in Chinese law or policy, the non-renewal or modification of our research authorization, deterioration in relations between the United States and China, tariffs, sanctions, export controls applicable to biological materials, genetic sequences, or laboratory equipment, or restrictions on cross-border transfers of data and materials, including under the Personal Information Protection Law and related data-export rules, could materially disrupt our operations or our ability to sell products produced in China in other markets.
Risks related to intellectual property and competition
10. Our cell lines and production methods may be difficult to protect, and we face competition. We rely substantially on trade secrets, confidentiality agreements, and restricted access, rather than patents, to protect our cell lines, peptide library, and process knowledge. We do not license our cell lines. Trade secrets may be misappropriated or independently developed, and enforcement across multiple jurisdictions may be costly or ineffective. We also compete with conventional protein producers and with other cultivated-meat and precision-fermentation companies, some of which have substantially greater resources than we do.
Risks related to our financial position
11. We have incurred operating losses since inception, expect to continue to incur them, and will require significant additional capital to expand production. We have funded our operations through private financings. Expansion of production capacity, including additional bioreactor capacity and downstream purification capacity for our Blood Curd line, requires significant capital and carries execution risk. Additional financing may not be available on acceptable terms, or at all, and could dilute existing shareholders.
Risks related to our reputation
12. Negative publicity, whether or not accurate, could harm our brand and our partner relationships. Our business attracts public attention disproportionate to our size. Media coverage, social media commentary, or public statements questioning the nature, safety, ethics, or authenticity of our products or our company, whether or not accurate, could reduce demand, deter partners, prompt regulatory inquiry, or impair our ability to recruit personnel.
Material contracts
The following agreements are considered material to the company's business. Copies, where permitted by their confidentiality provisions, are available to shareholders through the shareholder portal. Counterparties are named only where they have consented to disclosure.
| Agreement | Counterparty | Date |
|---|---|---|
| Contract Operations Agreement – Pingshan Production Facility | Linjiang Bioprocess Operations Co., Ltd. (临江生物工艺运营有限公司) | 2024, amended 2025 |
| Master Services Agreement – Porcine Scaffold Supply | Not disclosed | 2021 (renewed 2025) |
| Exclusive Supply Agreement – Farmed American Alligator | Myakka River Alligator Co. | 2026 |
| Co-Manufacturing and Packing Agreement – Blended Sausage (North America) | Not disclosed | 2025 |
| Supply Agreement – Serum-Free Media Components | Not disclosed | 2023 (amended 2025) |
| Lease – Shenzhen Production Facility, Pingshan District | Not disclosed | 2022 |
| Lease – Shenzhen Research Center, Nanshan District | Not disclosed | 2016 (renewed 2021) |
| Lease – Headquarters and Culinary Center, South San Francisco | Not disclosed | 2023 |
Nothing on this page constitutes an offer to sell, or a solicitation of an offer to buy, any security of Jurassic Meat. This summary is current as of December 1, 2026, and Jurassic Meat undertakes no obligation to update it.